DEPO-PROVERA® CI Patient Counseling Information

(medroxyprogesterone acetate injectable suspension, for intramuscular use)

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA‑approved patient labeling (Patient Information).

•
Advise patients at the beginning of treatment that their menstrual cycle may be disrupted and that irregular and unpredictable bleeding or spotting results, and that this usually decreases to the point of amenorrhea as treatment with Depo-Provera CI continues, without other therapy being required.
•
Counsel patients about the possible increased risk of breast cancer in women who use Depo-Provera CI [see Warnings and Precautions (5.3)].
•
Counsel patients that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections.
•
Counsel patients on Warnings and Precautions associated with use of Depo-Provera CI.
•
Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with Depo-Provera CI.

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

To contact Pfizer’s Medical Information Department please visit www.pfizermedinfo.com or call 1‑800‑438‑1985.

Find DEPO-PROVERA® CI medical information:

Find DEPO-PROVERA® CI medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

DEPO-PROVERA® CI Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Patient Counseling Information

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA‑approved patient labeling (Patient Information).

•
Advise patients at the beginning of treatment that their menstrual cycle may be disrupted and that irregular and unpredictable bleeding or spotting results, and that this usually decreases to the point of amenorrhea as treatment with Depo-Provera CI continues, without other therapy being required.
•
Counsel patients about the possible increased risk of breast cancer in women who use Depo-Provera CI [see Warnings and Precautions (5.3)].
•
Counsel patients that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections.
•
Counsel patients on Warnings and Precautions associated with use of Depo-Provera CI.
•
Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with Depo-Provera CI.

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

To contact Pfizer’s Medical Information Department please visit www.pfizermedinfo.com or call 1‑800‑438‑1985.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.